Cargando…
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661993/ https://www.ncbi.nlm.nih.gov/pubmed/31413539 http://dx.doi.org/10.2147/OPTH.S184706 |
_version_ | 1783439566606172160 |
---|---|
author | Yannuzzi, Nicolas A Freund, K Bailey |
author_facet | Yannuzzi, Nicolas A Freund, K Bailey |
author_sort | Yannuzzi, Nicolas A |
collection | PubMed |
description | Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care and treatment burden with currently available medications. Brolucizumab is a single-chain antibody fragment inhibitor of all isoforms of VEGF-A. Its small molecular weight allows for high solubility and tissue penetration. Brolucizumab has most recently been evaluated in 2 parallel phase 3 randomized controlled trials which demonstrated its safety and efficacy in an extended dosing regimen. The present review summarizes the safety, visual and anatomic outcomes, and durability of brolucizumab in the treatment of neovascular AMD and discusses some of the extended dosing regimens explored with currently approved medications and other therapies still under clinical investigation. |
format | Online Article Text |
id | pubmed-6661993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66619932019-08-14 Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration Yannuzzi, Nicolas A Freund, K Bailey Clin Ophthalmol Review Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care and treatment burden with currently available medications. Brolucizumab is a single-chain antibody fragment inhibitor of all isoforms of VEGF-A. Its small molecular weight allows for high solubility and tissue penetration. Brolucizumab has most recently been evaluated in 2 parallel phase 3 randomized controlled trials which demonstrated its safety and efficacy in an extended dosing regimen. The present review summarizes the safety, visual and anatomic outcomes, and durability of brolucizumab in the treatment of neovascular AMD and discusses some of the extended dosing regimens explored with currently approved medications and other therapies still under clinical investigation. Dove 2019-07-24 /pmc/articles/PMC6661993/ /pubmed/31413539 http://dx.doi.org/10.2147/OPTH.S184706 Text en © 2019 Yannuzzi and Freund. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Yannuzzi, Nicolas A Freund, K Bailey Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title | Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_full | Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_fullStr | Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_full_unstemmed | Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_short | Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_sort | brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661993/ https://www.ncbi.nlm.nih.gov/pubmed/31413539 http://dx.doi.org/10.2147/OPTH.S184706 |
work_keys_str_mv | AT yannuzzinicolasa brolucizumabevidencetodateinthetreatmentofneovascularagerelatedmaculardegeneration AT freundkbailey brolucizumabevidencetodateinthetreatmentofneovascularagerelatedmaculardegeneration |